Biomedical revitalization plan is not put around the “fever” – Biomedical – Pharmaceutical industries

According to data from the National Development and Reform Commission, the state biomedical industry is expected to revitalize the planning completed for 2-three months work. In countries with policy-oriented plans to release prior to, no time to wait for some provinces and cities already beginning gun for the country. It is understood that this proposed strategy, led by the National Development and Reform Commission, Ministry of Market, Ministry of Finance, Ministry of Science and other ministries involved in the formulation.

Biomedical “fever”

Yesterday (May possibly five), business analyst Lee his (her real name) told the Southern Metropolis Daily reporter said: “look back at the 2009 world’s leading ten pharmaceutical mergers and acquisitions, we know that our bio-pharmaceutical development, it is feasible only to transport ammunition and supplies giants only. “securities of another researcher also holds the identical view with his view that” the amount of output is a measure of some local governments struggle with foreign giants an crucial indicator of foreign biological system drug giant, but in the interest of new item development and marketing in China at each step. ” Nevertheless, individual professionals

this “bad-mouth” comment, does not avoid the development of Chinese bio-pharmaceutical high-speed growth momentum. Data show that in 2008 China’s output of 866.6 billion yuan to accomplish biomedical, bio-pharmaceuticals grew 30.65%. Total economic output last year, biopharmaceutical, or much more than 1 trillion.

Biomedicine is a national and local government “core methods in emerging industries,” the behavior of the market to start heating. According to information in choice-creating panoramic terminal data, bio-pharmaceutical business this year, significant capital and significant super funds reached 7.707 billion yuan total inflow only in April, there are five. billion of institutional funds into the plate. Release of funds from a quarterly perspective, a total of 38 fund companies are heavy in the initial quarter of biopharmaceuticals.

Policy Study Office of the State Development and Reform Commission warned Lee Park China: From a national perspective focused on the development of market and ultimately, biomedical business, but in different parts of the correct to select to meet the region’s strategic new industries.

Around the “live”

It is understood, Jiangsu, Shanghai, Beijing, Sichuan, Guangdong, Chongqing and other governments are implementing these new industry plan:

Sichuan Sichuan Province has listed bio-pharmaceutical, “12 5″ strategy sprint athletes in one of the output. Chengdu has introduced a strategy to create the “strive to Chengdu in 2012 biomedical market economy reached a total 90 billion yuan, sales revenue reached 80 billion yuan of corporate objectives.”

Jiangsu biomedical industry’s present annual output of about 200 billion yuan, the total size of about 11.5% of the country. Among them, the industrial enzyme, recombinant human insulin, genetically engineered endostatin and other leading drugs in the country. Jiangsu want to biopharmaceutical sales revenue in 2012 much more than 500 billion yuan, “the world’s biomedical innovation and industrialization of one of the most active.”

Beijing Biomedical Engineering by the end of April begin, short-listed organizations will take pleasure in a full range of policy support, including public financing, mergers and acquisitions as properly as access to credit. Beijing the next three years and strive to treat the biotechnology market from the present size of less than 400 billion yuan to 100 billion yuan.

The end of 2012, Shanghai plans to initially create innovative items of domestic manufacture of bio-medicine center, business center and R &amp D centers??? Biological pharmaceutical business reached 200 billion yuan of economic aggregate.

Chongqing will invest in the next three years, “1 hundred million yuan to construct a strategic emerging biopharmaceutical industry”, and strive to add value over 30 billion yuan.

Biopharmaceutical development momentum in Guangdong Province and other provinces are not poor, only the 2010 output is expected to reach Shenzhen, biomedical 100 000 000 000.